Connection

Co-Authors

This is a "connection" page, showing publications co-authored by GIULIO DRAETTA and RONALD A DEPINHO.
Connection Strength

1.754
  1. Cancer drug discovery faces the FACT. Sci Transl Med. 2011 Aug 10; 3(95):95ps34.
    View in: PubMed
    Score: 0.402
  2. Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell. 2019 Nov 14; 179(5):1239.
    View in: PubMed
    Score: 0.178
  3. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019 04; 568(7752):410-414.
    View in: PubMed
    Score: 0.171
  4. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature. 2017 02 02; 542(7639):119-123.
    View in: PubMed
    Score: 0.147
  5. In?Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016 06 28; 16(1):133-147.
    View in: PubMed
    Score: 0.141
  6. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016 Feb 15; 30(4):355-85.
    View in: PubMed
    Score: 0.138
  7. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res. 2015 Mar 15; 75(6):1091-101.
    View in: PubMed
    Score: 0.129
  8. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014 Jul 03; 158(1):185-197.
    View in: PubMed
    Score: 0.123
  9. Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. bioRxiv. 2024 Aug 08.
    View in: PubMed
    Score: 0.062
  10. Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. Cell Rep. 2019 01 08; 26(2):469-482.e5.
    View in: PubMed
    Score: 0.042
  11. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018 07; 24(7):1036-1046.
    View in: PubMed
    Score: 0.040
  12. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017 11; 18(11):e653-e706.
    View in: PubMed
    Score: 0.039
  13. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6.
    View in: PubMed
    Score: 0.038
  14. PRKCI promotes immune suppression in ovarian cancer. Genes Dev. 2017 06 01; 31(11):1109-1121.
    View in: PubMed
    Score: 0.038
  15. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017 02 16; 542(7641):362-366.
    View in: PubMed
    Score: 0.037
  16. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014 Oct 30; 514(7524):628-32.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.